Follicular Lymphoma Care: Bispecific Antibody Side Effects and Precautions
What bispecific antibody side effects and precautions should follicular lymphoma patients know about? Expert Dr. Kami Maddocks from The Ohio State University Wexner Medical Center discusses common bispecific antibody side effects and how patients can help safeguard themselves against potential infections.
Download Guide | Descargar Guía
See More from START HERE Follicular Lymphoma
Related Resources:
|
Bispecifics and CAR T for Follicular Lymphoma: What Patients Should Know |
Supporting Follicular Lymphoma Patients in Relapse: Expert Tips for Care Partners |
Transcript:
Lisa Hatfield:
I’m not sure if its Jefren of Jeffrey, is asking about the most common side effects that are associated with bispecific antibodies, and what precautions can be taken to reduce the risk of infection.
Dr. Kami Maddocks:
Yeah, another great question. There are two different bispecific antibodies that are now approved for relapsed/refractory follicular lymphoma. And I will take this time to also say that some of the exciting ongoing work is looking at those agents in clinical trials, in the frontline setting, in combination with other therapies particularly non-chemotherapies. In general, I would say similar side effect profile. The most common side effect between them is the cytokine release or the CRS. So that is the most common side effect. Again, this can be defined in different ways. The most common side effects that you see from that define CRS are fever, hypotension or low blood pressure, hypoxia or low oxygen, shortness of breath, chills, tachycardia or higher heart rate.
We have talked a lot about CRS and what it entails and how it is defined and presents. But management, it depends on what we call grading. So for patients who just, who have a fever, oftentimes, number one, you want to make sure that it is CRS and that there’s not an underlying cause. So ruling out infection or coexisting infection, if a patient is neutropenic or has a low neutrophil count and is at higher risk for infection, you may treat them with antibiotics with a fever while you rule out infection.
But oftentimes, if they have a fever, you can manage symptomatically anti-fever medications like acetaminophen (Tylenol). If a patient has worsening CRS and has other symptoms associated with it, such as the hypoxia, low oxygen, or hypotension, low blood pressure, then that’s when we escalate therapy. So one you direct treatment towards that. So if they need fluid, if they need oxygen, but then that’s when you’re thinking about starting medications such as the steroid medication. So we give intravenous dexamethasone (Decadron), or there are certain cytokine blockers such as tocilizumab (Actemra) that can be given to help treat the side effects of the cytokine release.
Other common side effects or that we’re seeing in more patients in the clinical trials, fatigue, rash, and then infections including upper respiratory infections, and then COVID-19 infection as well. So part of treatment of these side effects is early recognition of the side effects. So patients are monitored closely and that you’re dealing with the side effects to help them from worsening. I think infection prevention is very important with these.
So it’s recommended to consider prophylaxis for certain infections. So antiviral medication to prevent viral, such as shingles reactivation, medication to prevent a specific type of pneumonia, PJP pneumonia, and then consideration I think of just making sure that patients are up to date on vaccination. And if patients do have infection while they’re getting treated, potentially delaying treatment or taking a break in order for them to recover from treatment.
